Polymorphisms in the SULF1 gene are associated with early age of onset and survival of ovarian cancer

Journal of Experimental and Clinical Cancer Research

Volumn 30, Issue 1, 2011, Pages

  Han, Chan H ^a   Huang, Yu Jing ^a   Lu, Karen H ^a   Liu, Zhensheng ^a   Mills, Gordon B ^a   Wei, Qingyi ^a   Wang, Li E ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ALLELE; ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; GENE EXPRESSION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; ONSET AGE; OVARY CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SULFATASE 1 GENE; CANCER STAGING; FEMALE; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY;

SULF1 PROTEIN, HUMAN; SULFOTRANSFERASE;

AGE OF ONSET; AGED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; SULFOTRANSFERASES;

EID: 78650939811     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-30-5     Document Type: Article

References (36)

1. Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans. M Morimoto-Tomita K Uchimura Z Werb S Hemmerich SD Rosen, J Biol Chem 2002 277 49175 49185 10.1074/jbc.M205131200 12368295
2. QSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signaling. X Ai AT Do O Lozynska M Kusche-Gullberg U Lindahl CP Emerson Jr, J Cell Biol 2003 162 341 351 10.1083/jcb.200212083 12860968
3. Functions of cell surface heparan sulfate proteoglycans. M Bernfield M Gotte PW Park O Reizes ML Fitzgerald J Lincecum M Zako, Annu Rev Biochem 1999 68 729 777 10.1146/annurev.biochem.68.1.729 10872465
4. Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. D Liu Z Shriver Y Qi G Venkataraman R Sasisekharan, Semin Thromb Hemost 2002 28 67 78 10.1055/s-2002-20565 11885027 (Pubitemid 34194874)
5. Regulation of FGF-1 mitogenic activity by heparan sulfate oligosaccharides is dependent on specific structural features: differential requirements for the modulation of FGF-1 and FGF-2. DA Pye RR Vives P Hyde JT Gallagher, Glycobiology 2000 10 1183 1192 10.1093/glycob/10.11.1183 11087710
6. Glypicans in growth control and cancer. J Filmus, Glycobiology 2001 11 19R 23R 10.1093/glycob/11.3.19R 11320054
7. Angiogenesis-dependent diseases. J Folkman, Semin Oncol 2001 28 536 542 10.1016/S0093-7754(01)90021-1 11740806
8. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. RV Iozzo JD San Antonio, J Clin Invest 2001 108 349 355 11489925
9. Glypican-3 expression is silenced in human breast cancer. YY Xiang V Ladeda J Filmus, Oncogene 2001 20 7408 7412 10.1038/sj.onc.1204925 11704870
10. Regulation of Wnt signaling and embryo patterning by an extracellular sulfatase. GK Dhoot MK Gustafsson X Ai W Sun DM Standiford CP Emerson Jr, Science 2001 293 1663 1666 10.1126/science.293.5535.1663 11533491
11. Hsulf-1 regulates growth and invasion of pancreatic cancer cells. I Abiatari J Kleeff J Li K Felix MW Buchler H Friess, J Clin Pathol 2006 59 1052 1058 10.1136/jcp.2005.031716 16603650
12. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Lai J Chien J Staub R Avula EL Greene TA Matthews DI Smith SH Kaufmann LR Roberts V Shridhar, J Biol Chem 2003 278 23107 23117 10.1074/jbc.M302203200 12686563
13. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. JP Lai J Chien SE Strome J Staub DP Montoya EL Greene DI Smith LR Roberts V Shridhar, Oncogene 2004 23 1439 1447 10.1038/sj.onc.1207258 14973553
14. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. JP Lai JR Chien DR Moser JK Staub I Aderca DP Montoya TA Matthews DM Nagorney JM Cunningham DI Smith,, et al. Gastroenterology 2004 126 231 248 10.1053/j.gastro.2003.09.043 14699503
15. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. J Staub J Chien Y Pan X Qian K Narita G Aletti M Scheerer LR Roberts J Molina V Shridhar, Oncogene 2007 26 4969 4978 10.1038/sj.onc.1210300 17310998
16. Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics. AD Johnson D Wang W Sadee, Pharmacol Ther 2005 106 19 38 10.1016/j.pharmthera.2004.11.001 15781120
17. Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. AD Johnson Y Zhang AC Papp JK Pinsonneault JE Lim D Saffen Z Dai D Wang W Sadee, Pharmacogenet Genomics 2008 18 781 791 10.1097/FPC.0b013e3283050107 18698231
18. Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. CH Han Q Wei KK Lu Z Liu GB Mills LE Wang, Int J Clin Exp Med 2009 2 289 299 20057973
19. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. RF Ozols BN Bundy BE Greer JM Fowler D Clarke-Pearson RA Burger RS Mannel K DeGeest EM Hartenbach R Baergen, J Clin Oncol 2003 21 3194 3200 10.1200/JCO.2003.02.153 12860964
20. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther, J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437
21. IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration. LF Lee RP Hellendall Y Wang JS Haskill N Mukaida K Matsushima JP Ting, J Immunol 2000 164 2769 2775 10679119
22. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. TJ Shaw MK Senterman K Dawson CA Crane BC Vanderhyden, Mol Ther 2004 10 1032 1042 10.1016/j.ymthe.2004.08.013 15564135
23. Suppression of tumorigenicity in human ovarian carcinoma cell line SKOV-3 by microcell-mediated transfer of chromosome 11. Q Cao H Abeysinghe O Chow J Xu H Kaung C Fong P Keng RA Insel WM Lee JC Barrett N Wang, Cancer Genet Cytogenet 2001 129 131 137 10.1016/S0165-4608(01)00442-3 11566343
24. Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. J Li J Kleeff I Abiatari H Kayed NA Giese K Felix T Giese MW Buchler H Friess, Mol Cancer 2005 4 14 10.1186/1476-4598-4-14 15817123
25. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. R Nawroth A van Zante S Cervantes M McManus M Hebrok SD Rosen, PLoS One 2007 2 392 10.1371/journal.pone.0000392 17460759
26. Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. GC Jayson M Lyon C Paraskeva JE Turnbull JA Deakin JT Gallagher, J Biol Chem 1998 273 51 57 10.1074/jbc.273.1.51 9417046
27. Heparin-degrading sulfatases in hepatocellular carcinoma: roles in pathogenesis and therapy targets. JP Lai JR Thompson DS Sandhu LR Roberts, Future Oncol 2008 4 803 814 10.2217/14796694.4.6.803 19086847
28. The tumor suppressor function of human sulfatase 1 (SULF1) in carcinogenesis. JP Lai DS Sandhu AM Shire LR Roberts, J Gastrointest Cancer 2008 39 149 158 10.1007/s12029-009-9058-y 19373441
29. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo. K Narita J Staub J Chien K Meyer M Bauer A Friedl S Ramakrishnan V Shridhar, Cancer Res 2006 66 6025 6032 10.1158/0008-5472.CAN-05-3582 16778174
30. Regulation of neuronal survival by the serine-threonine protein kinase Akt. H Dudek SR Datta TF Franke MJ Birnbaum R Yao GM Cooper RA Segal DR Kaplan ME Greenberg, Science 1997 275 661 665 10.1126/science.275.5300.661 9005851
31. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. S Gibson S Tu R Oyer SM Anderson GL Johnson, J Biol Chem 1999 274 17612 17618 10.1074/jbc.274.25.17612 10364198
32. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. MJ Koury MC Bondurant, Science 1990 248 378 381 10.1126/science.2326648 2326648
33. The hallmarks of cancer. D Hanahan RA Weinberg, Cell 2000 100 57 70 10.1016/S0092-8674(00)81683-9 10647931
34. Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer. S Junnila A Kokkola T Mizuguchi K Hirata ML Karjalainen-Lindsberg P Puolakkainen O Monni, Genes Chromosomes Cancer 2009 49 28 39 10.1002/gcc.20715
35. Expression of novel extracellular sulfatases Sulf-1 and Sulf-2 in normal and osteoarthritic articular cartilage. S Otsuki N Taniguchi SP Grogan D D'Lima M Kinoshita M Lotz, Arthritis Res Ther 2008 10 61 10.1186/ar2432 18507859
36. Cancer statistics, 2008. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun, CA Cancer J Clin 2008 58 71 96 10.3322/CA.2007.0010 18287387